Pharmacokinetic and pharmacodynamic properties of ALX-0081 after single IV administration to cynomolgus monkeys. Different doses of ALX-0081 were administered as an IV bolus injection: 0.02 mg/kg (○, dotted lines), 0.40 mg/kg (□, dashed lines), or 8.00 mg/kg (▵, solid lines); n = 6 for each dose level, except for the 8.00 mg/kg group, where one animal was considered an outlier because of a nondecreasing profile and was therefore excluded from the analysis (n = 5). (A) Mean (± SD) observed ALX-0081 plasma concentrations are shown in function of time. (B) RICO (mean ± SEM) was determined as a measure for the inhibitory effect of ALX-0081 on VWF-mediated platelet aggregation.